ROCHESTER, MI–(Marketwired – March 09, 2016) – OptimizeRx Corp. (OTCQB: OPRX), a software company whose premier content-delivery platform enables pharmaceutical companies to provide on-demand patient-savings and support services right at point of prescribe, will hold a conference call on Tuesday, March 15, 2016 at 5:30 p.m. Eastern time to discuss results for the fourth quarter and full year ended December 31, 2015. The financial results will be issued in a press release prior to the call.
OptimizeRx management will host the presentation, followed by a question and answer period.
Date: Tuesday, March 15, 2016
Time: 5:30 p.m. Eastern time (2:30 p.m. Pacific time)
Toll-free dial-in number: 1-888-572-7025
International dial-in number: 1-719-457-2697
Conference ID: 3542013
Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1-949-574-3860.
A replay of the call will be available after 8:30 p.m. Eastern time on the same day through April 5, 2016, as well as available for replay via the Investors section of OptimizeRx’s website at www.optimizerxcorp.com.
Toll-free replay number: 1-877-870-5176
International replay number: 1-858-384-5517
Replay ID: 3542013
About OptimizeRx Corporation
OptimizeRx Corporation (OTCQB: OPRX) provides unique consumer and physician platforms to help patients better afford and comply with their medicines and healthcare products, while offering pharmaceutical and healthcare companies effective ways to expand awareness, access and adherence to their medications.
The company’s core product, SampleMD™, replaces drug samples with electronic trial vouchers and copay coupon savings, which are added to an e-Prescription and electronically sent to the pharmacy. SampleMD is integrated within leading Electronic Health Record (EHR) platforms, including Allscripts, Quest Diagnostics, Practice Fusion and Dr. First, reaching over 350 EHRs.
Investor Relations Contact:
Senior Managing Director